ROS1 and non-small cell lung carcinoma: Hence, for patients with advanced NSCLC, ESMO recommends determining PD-L1 expression between others such as EGFR testing, BRAF mutations, and the analysis of ALK, ROS1, and NTRK rearrangements [71].